Emerging role of MYB transcription factors in cancer drug resistance  

作　　者：Bernhard Biersack Michael Höpfner 

机构地区：[1]Organic Chemistry Laboratory,University of Bayreuth,Bayreuth 95440,Germany [2]Institute for Physiology,Charité-Universitätsmedizin Berlin,Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin,Berlin 10117,Germany

出　　处：《Cancer Drug Resistance》2024年第1期797-832,共36页癌症耐药(英文)

摘　　要：Decades ago,the viral myeloblastosis oncogene v-myb was identified as a gene responsible for the development of avian leukemia.However,the relevance of MYB proteins for human cancer diseases,in particular for solid tumors,remained basically unrecognized for a very long time.The human family of MYB transcription factors comprises MYB(c-MYB),MYBL2(b-MYB),and MYBL1(a-MYB),which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs.In addition to overexpression,the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers.The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens.In addition,new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way.This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.

关 键 词：Anticancer drugs MYB transcription factors ONCOGENES drug resistance cancer resistance mechanisms MYB-targeting drugs 

分 类 号：R73[医药卫生—肿瘤]